Positive Trial Data Supports 43% Upside for Immuneering Corporation (IMRX)

Immuneering Corporation (NASDAQ:IMRX) is among the best fast money stocks to buy now. Analysts at Mizuho have reaffirmed their ‘Outperform’ rating on Immuneering Corporation (NASDAQ:IMRX), while maintaining a price target of $10, implying a surge of about 43%. This optimism stems from the company’s positive clinical trial outcome for its lead drug candidate.

On Wednesday, Immuneering Corporation (NASDAQ:IMRX) reported modified 9-month survival data from its Phase 2a trial of atebimetinib (atebi), together with updated gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients. The data, collected from 34 patients, reflected overall survival and progression-free survival results that not only surpassed the traditional standard-of-care treatments, but also the research firm’s own expectations.

What keeps the investor’s interest is the company’s atebimetinib, which has the potential to become a top-tier treatment for first-line pancreatic cancer patients. With the results demonstrating enhanced durability in contrast to the previous 6-month data update from June, we have a good reason to believe in the prospects of the drug, and ultimately Immuneering Corporation (NASDAQ:IMRX).

Immuneering Corporation (NASDAQ:IMRX) is a Massachusetts-based clinical-stage oncology company specializing in treatments targeting broad populations of cancer patients. Founded in 2008, the company is committed to developing innovative medicines.

While we acknowledge the potential of IMRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.